We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Value of TaqMan® Drug Metabolism Genotyping Assays Validated

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Value of TaqMan® Drug Metabolism Genotyping Assays Validated"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Scientists from Applied Biosystems have presented data demonstrating the accuracy of TaqMan® Drug Metabolism Genotyping Assays in identifying variation in genes that code for drug metabolism enzymes.

Identifying these variations is important in both drug development and clinical research, as they are associated with certain diseases such as cancer, and have been shown to significantly impact drug efficacy.

The data, presented at the 56th annual meeting of the American Society of Human Genetics, was based on the use of approximately 2,400 markers from the TaqMan Drug Metabolism Enzyme panel examining genetic variation across the International HapMap Project and SNP500Cancer populations.

Assays were measured for their reproducibility, signal intensity, and the ability to make genotype calls.

Reference data from this study will be publicly available on the National Cancer Institute's SNP500Cancer website as well as the Pharmacogenomics Knowledge Base, a publicly available internet research tool to help researchers understand how genetic variation relates to individual differences in reactions to drugs.